Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behcet's disease

Dermatology

Volumn 198, Issue 3, 1999, Pages 243-246

  Örem, Asim ^a,b   Cimsit G ^a   Deger O ^a   Vanizor, B ^a   Karahan, S C ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Behcet's disease; Lipoproteins; Oxidation

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AUTOANTIBODY; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARKER; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BEHCET DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; APOLIPOPROTEINS B; AUTOANTIBODIES; BEHCET SYNDROME; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 16744365391     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018122     Document Type: Article

References (24)

1. O'Duffy JD: Vasculitis in Behçet's disease. Rheum Dis Clin North Am, 1990;16:423-431.
2. Pronai L, Ichikawa Y, Nakazawa H, Arimory S: Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leukocytes in Behçet's disease -Effects of colchicine. Clin Exp Rheum 1991; 9:227-233.
3. Deǧer O, Örem A, Akyol N, Bahadir S, Yildirmiş, S: PMN elastase levels in patients with Behçet's disease. Clin Chim Acta 1995;236: 129-134.
4. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M: Auto-oxidative damage in Behçet's disease -Endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982;49: 247-255.
5. Doǧan P, Soyuer Ü, Tanrikulu G, Utas S: Changes in serum and polymorphonuclear anti-oxidant defense systems in Behçet's disease. Invest Dermatol 1989;93:297-298.
6. Doǧan P, Tanrikulu G, Soyuer Ü, Köse K: Oxidative enzymes of polymorphonuclear leukocytes and plasma fibrinogen, ceruloplasmin and copper levels in Behçet's disease. Clin Biochem 1995;27:413-418.
7. Mitamura T, Ohno S, Ariga H, Ohsaka T, Iwasaki N, Matsuda H, Matsumiya H: Lipoprotein cholesterol concentrations in patients with Behçet's disease. Clin Chim Acta 1988;175:277-284.
8. Örem A, Deǧer O, Memiş, Ö, Bahadir S, Ovali E, Çimşit G: Lp (a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease. Ann Rheum Dis 1995;54:726-729.
9. Örem A, Efe H, Deǧer O, Çimşit G, Uydu HA, Vanizor B: Relationship between lipid peroxidation and disease activity in patients with Behçet's disease. J Dermatol Sci 1997;16: 11-16.
10. Yla-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Atheroscler Thromb 1994;14:32-40.
11. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1791.
12. Lopes-Virella MR, Virella G: Atherosclerosis and autoimmunity. Clin Immunol Immunopathol 1994;73:155-167.
13. International Study Group for Behçst's Disease: Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-1080.
14. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:467-479.
15. Craig W: Autoantibodies against oxidized low density lipoprotein: A review of clinical findings and assay methodology. J Clin Lab Anal 1995;9:70-74.
16. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew RE, Steinberg D, Witztum JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-1376.
17. Puurunen M, Manttari M, Manninen V: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-2609.
18. Maggi E, Finardi G, Polşi M, Bollati P, Fillipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E: Specificity autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coronary Artery Dis 1993;4: 1119-1122.
19. Bellona G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G: Autoantibodies against oxidatively modified LDL in NIDDM. Diabetes 1995;44:60-66.
20. Maggi E, Bellezzi R, Gazo A, Seccia M, Bellona G: Autoantibodies against oxidatively modified LDL in uremic patients undergoes dialysis. Kidney Int 1994;46:869-876.
21. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpella H, Salonen R, Nyyssönen K, Palinski W, Witztum JL: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-886.
22. Vaarala O, Alfthan G. Jauhiainen N, Leirisalo-Repo M, Aho K, Palosuo T: Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-925.
23. Paimela L, Helva T, Leirisalo-Repo M, Vaarala O, Alfthan G, Palosuo T, Aho K: Clinical significance of antibodies against oxidized low density lipoprotein in early RA. Ann Rheum Dis 1996;55:558-559.
24. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF: Anti-oxidized low density lipoprotein antibodies in patients with coronary disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-101.